Psychedelic

N,N-DMT (Dimethyltryptamine)

Powerful, short-acting psychedelic tryptamine found in many plants and animals. Produces intense visual and psychological effects.

Important information

This information is for educational purposes only. Always research thoroughly, test your substances, understand legal implications, and consult healthcare professionals. Never use substances alone or in unsafe environments.

Dosage information

N,N-DMT · Vaporized · non-clinical reference ranges

Tier labels reproduce reported amount and intensity terminology; they do not indicate safety or a recommendation.

Reference dose ranges for N,N-DMT by Vaporized, in milligrams
TierAmountNote
Light 10 to 20 milligrams
Common 20 to 40 milligrams
Strong 40 to 60 milligrams
Breakthrough Reported lower bound: 60 milligrams; no upper bound is established.

Dosage ranges are reference values from published literature, not recommendations. Potency varies by source, body weight, and individual sensitivity — harm-reduction practice starts well below the ranges listed.

Limitations: Figures are transcribed from a reference compilation, not measured in a controlled study; the potency of any given material is unknown until tested.

Evidence: Review or reference work

  1. Erowid Erowid DMT Vault

Duration

Vaporized: 5-15 minutes total | Oral with MAOI: 2-6 hours

Effect timeline · Vaporized
Onset 0m–1m Comeup 1m–2m Peak 3m–8m Offset 5m–10m Afterglow 15m–60m

Vaporized: 5-15 minutes active. Extremely rapid onset.

Effect timeline · Oral
Onset 30m–60m Comeup 30m–60m Peak 60m–2h Offset 60m–2h Afterglow 60m–3h

Oral with MAOI (ayahuasca): 2-6 hours. Requires MAOI to be active orally.

Known interactions

Caution N,N-DMT + MDMA (Ecstasy/Molly)

DMT is commonly consumed with MAOIs in ayahuasca preparations. MDMA combined with MAOIs is life-threatening. Ensure MAOI has fully cleared before MDMA use.

Risks: Serotonin syndrome (potentially fatal) · Hyperthermia · Seizures · Hypertensive crisis

Mechanism: MAO inhibition prevents serotonin breakdown; MDMA floods serotonin. Combined = serotonin syndrome.

What reduces the risk

  • If using ayahuasca, wait at least 2 weeks before MDMA
  • Never combine MDMA with any MAOI
  • Know if your DMT preparation contains MAOIs

Sources: TripSit Interaction Chart · PsychonautWiki: MDMA Interactions · Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005

Absence of a listed interaction never implies safety. Check any combination in the app's 23×23 interaction matrix.

Harm reduction

  • Comfortable, safe location
  • Sitter highly recommended
  • Sitting or lying position
  • Test substance
  • Start with lower dose
  • Mental preparation

Risks & side effects

  • Overwhelming intensity
  • Psychological distress
  • Cardiovascular strain
  • Dangerous with MAOIs
  • HPPD (rare)

Effects

  • Breakthrough experiences
  • Entity encounters
  • Geometric visual patterns
  • Time dissolution
  • Profound insights
  • Spiritual experiences

Schedule I in most countries. Naturally occurring in many plants.

Pharmacology

5-HT2A receptor agonist. Naturally occurs in human body. Broken down by MAO.

Therapeutic research

  • Rick Strassman's pioneering study: First FDA-approved psychedelic research in a generation (1990–1995)
  • Imperial College London: DMT neuroimaging studies revealing brain dynamics during altered states (Timmermann et al., 2019)
  • Ayahuasca research: Antidepressant effects in treatment-resistant depression (Palhano-Fontes et al., 2019)
  • Small Pharma (now Cybin): Phase 2a trial of DMT-assisted therapy for major depressive disorder
  • Research into DMT's role as an endogenous compound — found naturally in human cerebrospinal fluid
  • Studies on near-death-like experiences induced by DMT (Imperial College, 2018)

Clinical studies 20

Human brain effects of DMT assessed via EEG-fMRI

Timmermann et al. 2023 PNAS study using combined EEG-fMRI to map DMT's effects on brain activity in 20 healthy volunteers. First study to capture DMT's neural signature with this methodology.

DMT alters cortical travelling waves

Alamia et al. 2020 eLife study showing DMT alters direction and magnitude of oscillatory travelling waves in visual cortex during eyes-closed states.

A Model for Target-Controlled Intravenous Infusion for Prolonged DMT Experience

Gallimore & Strassman 2016 paper proposing methodology for extended-state DMT research using anesthesiology infusion techniques. Published in Frontiers in Pharmacology.

The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization

Frecska, Bokor, Winkelman 2016 Frontiers in Pharmacology. Comprehensive review of ayahuasca's potential therapeutic applications including depression, addiction, and autoimmune disorders. Discusses sigma-1 receptor mechanisms.

Effects of DMT on Mental Health Outcomes

Explores the impact of DMT on mental health, analyzing datasets from prospective studies.

Psychedelics Promote Structural and Functional Neural Plasticity

Ly, Olson et al. 2018 Cell Reports landmark paper showing DMT promotes dendritic arbor complexity, spinogenesis, and synaptogenesis comparable to ketamine. Foundational neuroplasticity evidence.

N,N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function

Barker 2018 Frontiers in Neuroscience comprehensive review of endogenous DMT research. Examines DMT biosynthesis in humans, its presence in brain tissue, and potential physiological roles.

Rapid antidepressant effects of ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

Palhano-Fontes et al. 2018 Psychological Medicine first RCT of ayahuasca for depression. Showed significant antidepressant effects within 1-7 days in treatment-resistant patients.

Harmine produces antidepressant-like effects via restoration of astrocytic functions

Liu et al. 2017 study on harmine (MAO inhibitor in ayahuasca). Shows harmine has antidepressant effects by restoring astrocyte function, independent of DMT. Published in Prog Neuropsychopharmacol Biol Psychiatry.

N,N-dimethyltryptamine and the pineal gland: Separating fact from myth

Nichols 2017 critical review examining claims about pineal DMT. Concludes endogenous DMT concentrations are far too low to produce psychoactive effects. Important for scientific accuracy. Published in J Psychopharmacology.

Survey of entity encounter experiences occasioned by inhaled DMT

Davis, Griffiths et al. 2020 Johns Hopkins survey (N=2,561). Majority reported entity encounters during DMT experiences. 58% met criteria for 'mystical experience'. Published in J Psychopharmacology.

Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents

Cameron, Olson et al. 2019 ACS Chemical Neuroscience. First study showing chronic microdosing with DMT produces positive mood and anxiety effects in rodents. Important for microdosing research.

Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder

Zeifman et al. 2020 Psychopharmacology. Single-dose ayahuasca produced rapid and sustained reductions in suicidal ideation in treatment-resistant depression patients.

Neural correlates of the DMT experience assessed with multivariate EEG

Timmermann et al. 2019 Scientific Reports. EEG study revealing DMT increases oscillatory power at lower frequencies and increases signal diversity, correlating with subjective intensity.

Psychological and physiological effects of extended DMT

Luan, Rosas et al. 2023 PsyArXiv Preprint. First study using continuous IV infusion to maintain extended DMT state. Documented psychological and physiological effects over 30+ minutes.

Ayahuasca for the Treatment of Depression

Palhano-Fontes et al. 2021 Current Topics in Behavioral Neurosciences. Review of ayahuasca clinical trials for depression, including RCT evidence and neurobiological mechanisms.

Dimethyltryptamine (DMT) and ibogaine elicit membrane effects in HEK cells transiently transfected with the human 5-HT2A receptor

Eliasen et al. 2025 Brain Research. Study showing DMT and ibogaine produce distinct membrane effects via 5-HT2A receptor binding in transfected cells.

Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects

Aicher et al. 2024 Frontiers in Psychiatry. Controlled trial testing ayahuasca-inspired DMT+harmine formulation in healthy volunteers for safety and acute effects.

Ayahuasca: pharmacology, safety, and therapeutic effects

dos Santos, Hallak 2025 CNS Spectrums. Comprehensive review of ayahuasca/DMT pharmacology, safety profile, toxicity data, and therapeutic applications.

Psychoactive effects and toxicity of tryptamine, N-methyltryptamine (NMT), and N,N-dimethyltryptamine (DMT): quantification methods

Paley 2021 Protein Biosynthesis Interference in Disease. Chapter on DMT toxicity, psychoactive effects, and analytical methods for quantifying tryptamines.

Sources 2

  1. Griffiths, R. R., et al. Classic hallucinogens and mystical experiences: phenomenology and neural correlates. Current Topics in Behavioral Neurosciences, 36, pp. 393-430 (2018) doi:10.1007/7854_2017_474
  2. Erowid Erowid DMT Vault

History & culture

DMT has been used for millennia in South American shamanic traditions, primarily as ayahuasca — a brew combining DMT-containing plants (Psychotria viridis or Mimosa hostilis) with MAO-inhibiting Banisteriopsis caapi vine. Archaeological evidence from a 1,000-year-old ritual bundle found in Bolivia contained DMT, harmine, and cocaine residues. The compound was first synthesized by Canadian chemist Richard Manske in 1931, but its psychoactive properties weren't recognized until Hungarian chemist Stephen Szára self-administered it in 1956. Rick Strassman's groundbreaking DEA-approved study at the University of New Mexico (1990–1995) earned DMT the nickname 'The Spirit Molecule.'

Natural origins

DMT occurs widely in nature — found in hundreds of plant species across families including Fabaceae, Acanthaceae, and Rubiaceae. Key sources include Psychotria viridis (chacruna, used in ayahuasca), Mimosa tenuiflora (jurema, Brazilian traditional use), and Anadenanthera peregrina (yopo snuff). DMT is also endogenous to mammals, including humans — it has been detected in human blood, urine, and cerebrospinal fluid, though its physiological role remains debated. The Bufo alvarius toad contains 5-MeO-DMT (not N,N-DMT).

Molecular family: Tryptamines

Tryptamines are a class of indole-based compounds derived from tryptophan, an amino acid. This family includes some of the most powerful and well-studied psychedelics. The indole nucleus is conserved across all members, with variations in alkyl side chains and ring substitutions determining pharmacological effects. Tryptamines are found naturally in plants and fungi, with psilocybin being the most famous. Key characteristics: - Based on indole (benzene fused with pyrrole) - Often possess dimethylamino side chains - Range from mild (5-MeO-DMT) to extremely potent (DMT) - Found in nature: psilocybin mushrooms, ayahuasca, certain toads - Tend toward serotonergic mechanisms Members demonstrate remarkable diversity in intensity and duration despite similar core structure. Their indole foundation provides stability while allowing nature to create compounds spanning from gentle to overwhelming in effect.

Structurally related to Serotonin (5-HT)

External resources